MedTrace Logo

Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion

NCT04905251 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 129

Last updated 2025-02-10

No results posted yet for this study

Summary

National multi-center non interventional study aiming at investigating the effectiveness and safety of the combination mifepristone-misoprostol prescribed in Canada to women for medical termination of pregnancy at or before 63 days gestational age through a multi-center prospective non interventional study design.

Conditions

  • Medical Abortion

Interventions

DRUG

Mifepristone-Misoprostol

Non interventional design.

Sponsors & Collaborators

  • Linepharma International LTD

    lead INDUSTRY

Principal Investigators

  • Dustin COSTESCU, MDMS FRCSC · McMaster University Medical Centre - Hamilton ON Canada

Eligibility

Min Age
16 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-19
Primary Completion
2024-02-20
Completion
2024-02-20

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04905251 on ClinicalTrials.gov